학술논문
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients
Document Type
article
Author
Sara De Biasi; Domenico Lo Tartaro; Anita Neroni; Moritz Rau; Nikolaos Paschalidis; Rebecca Borella; Elena Santacroce; Annamaria Paolini; Lara Gibellini; Alin Liviu Ciobanu; Michela Cuccorese; Tommaso Trenti; Ignacio Rubio; Francesca Vitetta; Martina Cardi; Rafael José Argüello; Diana Ferraro; Andrea Cossarizza
Source
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Subject
Language
English
ISSN
2041-1723
Abstract
Abstract Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.